First randomized controlled trial shows promise of a ketogenic diet in psychotic disorders

by University of California, San Francisco

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar 1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared with diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric and cognitive measures.

Of the 58 participants enrolled, 47 completed the initial comparison between a one-month ketogenic diet intervention and a diet-as-usual control group. Twenty-five participants opted to continue the intervention for a total of four months in a single-arm extension. The study showed high feasibility, with 83% of daily tested participants maintaining ketosis in the one-month RCT portion and 94% in the four-month extension, with no reports of significant side effects from the diet.

After one month on the ketogenic diet, participants showed statistically significant improvements in key metabolic markers compared with the control group. In this controlled trial, higher ketone levels were associated with reductions in blood glucose and lower depression symptoms (PHQ-9), even after accounting for weight loss, suggesting that ketosis itself, rather than weight reduction alone, may play a role in the observed effects.

The four-month extension demonstrated that metabolic improvements were sustained alongside significant reductions in depression and schizophrenia symptoms, as well as enhanced cognitive performance. While this was a 25-participant single-arm extension, it represents an encouraging signal that the ketogenic diet is a potential intervention for serious mental illness.

"The improvement we saw in cognitive and psychological symptoms is particularly important in people with psychotic disorders because current medications that address their psychosis don't address their overall mental well-being, including cognitive or depressive symptoms, which can be debilitating," said study lead Judith M. Ford, Ph.D., professor of psychiatry at UCSF and the Weill Institute for Neurosciences. Ford noted that while the findings are encouraging, they underscore the need for larger, longer, fully controlled trials to establish whether these benefits hold up at scale.

The authors emphasize that a one-month intervention appears insufficient to capture the potential therapeutic mental health benefits of the intervention and that the significant cognitive and psychiatric improvements seen at four months need to be replicated under controlled conditions. These results align with recent pilot studies in schizophrenia and bipolar disorder and together indicate the need for larger, extended randomized controlled trials to test the efficacy and safety of ketogenic therapy in patients with serious mental illness.

"This study reinforces the evidence that ketogenic therapy is a feasible, safe and potentially transformative treatment for serious mental illness," said Jan Ellison Baszucki, co-founder and president of Baszucki Group, who was among the funders of the study. "Now is the time for diverse and sustained investment in rigorous scientific examination of metabolic approaches to psychiatry to expand the scope of these studies and to raise awareness of its potential."

More information

Samantha V Abram et al, Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial, Schizophrenia Bulletin (2026). DOI: 10.1093/schbul/sbag082

Key medical concepts

Diet, KetogenicPsychotic DisordersKetosis

Clinical categories

PsychiatryPsychology & Mental healthNutrition & Healthy eating Provided by University of California, San Francisco Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: First randomized controlled trial shows promise of a ketogenic diet in psychotic disorders (2026, July 8) retrieved 9 July 2026 from https://medicalxpress.com/news/2026-07-randomized-trial-ketogenic-diet-psychotic.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.